ELTROMBOPAG

Search structure
Trade Names:
Synonyms:
Status: Approved (2008)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: B02BX05
UNII: S56D65XJ9G

Structure
InChI Key XDXWLKQMMKQXPV-QYQHSDTDSA-N
Smile CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
InChI
InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H22N4O4
Molecular Weight 442.48
AlogP 4.56
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 5.0
Polar Surface Area 114.59
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 33.0

Pharmacology

Primary Target
Thrombopoietin receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 631-690 - - -
Membrane receptor
38-38 - - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - 14900 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Purpura, Thrombocytopenic, Idiopathic 3 D016553 ClinicalTrials
Thrombocytopenia 3 D013921 ClinicalTrials
Anemia, Aplastic 3 D000741 ClinicalTrials
Hepatitis C 3 D006526 ClinicalTrials
Hepatitis C, Chronic 3 D019698 ClinicalTrials
Neoplasms 3 D009369 ClinicalTrials
Anemia, Aplastic 3 D000741 ClinicalTrials
Fanconi Anemia 2 D005199 ClinicalTrials
Liver Diseases 2 D008107 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Blood Platelet Disorders 2 D001791 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Wiskott-Aldrich Syndrome 2 D014923 ClinicalTrials
Anemia 1 D000740 ClinicalTrials
Osteosarcoma 1 D012516 ClinicalTrials
Liver Cirrhosis 1 D008103 ClinicalTrials
Multiple Myeloma 0 D009101 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Nausea 33.0
General disorders and administration site conditions Asthenia 28.0
General disorders and administration site conditions Fatigue 28.0
Respiratory, thoracic and mediastinal disorders Cough 23.0
Gastrointestinal disorders Diarrhoea 21.0
Nervous system disorders Headache 21.0
Musculoskeletal and connective tissue disorders Pain in extremity 19.0
Investigations Body temperature increased 14.0
Cardiac disorders Dizziness 14.0
Cardiac disorders Dyspnoea 14.0
Blood and lymphatic system disorders Febrile neutropenia 14.0
Gastrointestinal disorders Oropharyngeal pain 14.0
Gastrointestinal disorders Abdominal pain 12.0
Musculoskeletal and connective tissue disorders Arthralgia 12.0
Blood and lymphatic system disorders Ecchymosis 12.0
Gastrointestinal disorders Gastrointestinal pain 12.0
Musculoskeletal and connective tissue disorders Muscle spasms 12.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 12.0
Infections and infestations Nasopharyngitis 12.0
Respiratory, thoracic and mediastinal disorders Rhinorrhoea 12.0
Investigations Transaminases increased 12.0
Nervous system disorders Headache 10.0
Gastrointestinal disorders Diarrhoea 9.0
Gastrointestinal disorders Nausea 9.0
Gastrointestinal disorders Diarrhoea
Infections and infestations Upper respiratory tract infection 7.0
Investigations Alanine aminotransferase increased 6.0
Blood and lymphatic system disorders Hyperbilirubinaemia 6.0
Infections and infestations Upper respiratory tract infection
Gastrointestinal disorders Vomiting 6.0
Investigations Alanine aminotransferase increased 5.0
Eye disorders Cataract 5.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 5.0
Musculoskeletal and connective tissue disorders Myalgia 5.0
Infections and infestations Urinary tract infection 5.0
Investigations Aspartate aminotransferase increased 4.0
General disorders and administration site conditions Asthenia 4.0
General disorders and administration site conditions Fatigue 4.0
Gastrointestinal disorders Nausea 4.0
Gastrointestinal disorders Oropharyngeal pain 4.0
Gastrointestinal disorders Pharyngitis 4.0
Investigations Alanine aminotransferase increased
Musculoskeletal and connective tissue disorders Back pain 3.0
Skin and subcutaneous tissue disorders Dermatitis 3.0
Infections and infestations Influenza 3.0
Gastrointestinal disorders Nausea
Gastrointestinal disorders Oropharyngeal pain
Nervous system disorders Paraesthesia 3.0
Skin and subcutaneous tissue disorders Rash 3.0
Infections and infestations Urinary tract infection
Investigations Aspartate aminotransferase increased
Musculoskeletal and connective tissue disorders Back pain
Skin and subcutaneous tissue disorders Dermatitis
Infections and infestations Influenza
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Myalgia
Nervous system disorders Paraesthesia
Gastrointestinal disorders Pharyngitis
Skin and subcutaneous tissue disorders Rash
Gastrointestinal disorders Vomiting

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Vascular disorders
60.0
Cardiac disorders
20.0
Nervous system disorders
20.0

Cross References

Resources Reference
CAS NUMBER 496775-61-2
ChEBI 85010
ChEMBL CHEMBL461101
DrugBank DB06210
DrugCentral 4399
FDA SRS S56D65XJ9G
Guide to Pharmacology 6961
SureChEMBL SCHEMBL211081
ZINC ZINC000011679756
CONTENTS